Proathlete Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Proathlete Wealth Management's BMY Position: Q3 2026 in Review
Proathlete Wealth Management increased its Bristol-Myers Squibb (BMY) stake by 34% in Q3 2026, buying an estimated $19.8K and bringing the position to 1,244 shares worth $77.6K. The position accounts for 0.02% of the portfolio, ranked #121.
Proathlete Wealth Management first reported a position in BMY in Q1 2025 and has held it in 7 quarters since. The position peaked at $149K in Q1 2025. 2,558 funds tracked by Wall St. Rank hold BMY as of Q3 2026.
- Proathlete Wealth Management held 1,244 shares of Bristol-Myers Squibb worth $77.6K as of Q3 2026.
- Proathlete Wealth Management bought 314 Bristol-Myers Squibb shares in Q3 2026, an estimated $19.8K.
- Bristol-Myers Squibb made up 0.02% of Proathlete Wealth Management's portfolio in Q3 2026, its #121 holding.
- Proathlete Wealth Management first reported a position in Bristol-Myers Squibb in Q1 2025 and has held it in 7 quarters since.
- Proathlete Wealth Management's Bristol-Myers Squibb position peaked at $149K in Q1 2025.
- 2,558 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.
Based on Proathlete Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.